ARA-290 and B7-33: Erythropoietin and Relaxin Peptides in Receptor Research

Two peptides from different parent proteins

ARA-290 and B7-33 share one feature: neither is a random sequence. Both are short fragments designed from larger proteins. The first was derived from erythropoietin (EPO), the second from relaxin-2. Both molecules appear in studies where what matters is the engagement of one specific receptor in an experimental model, not the length of the chain alone. Below we compare the two compounds and show how to prepare them for laboratory work.

ARA-290 (cibinetide): a fragment of erythropoietin

ARA-290, also known as cibinetide, is a peptide made of 11 amino acids. Erythropoietin controls red blood cell production, and its classic action through the EPOR receptor leads to erythropoiesis. ARA-290 was rebuilt from the surface of helix B of that protein as an independent peptide, and this difference is what draws attention to it. In research descriptions it does not stimulate blood cell production, which is why it is analyzed in the context of tissue protection rather than hematopoiesis. For a researcher this distinction matters, because it allows checking whether a protective response can occur without stimulating blood cell formation.

Mechanism described in the literature

According to the literature, ARA-290 activates the innate repair receptor (IRR), formed by EPOR and the CD131 subunit, also called the common beta subunit. Signaling through this complex is studied as a mechanism that limits damage to cells and tissues. In experimental models, descriptions include reduced apoptosis, modulation of the inflammatory response and improved nerve function in models of neuropathy.

B7-33: a single-chain relaxin-2 analogue

B7-33 is a synthetic peptide designed on the basis of relaxin-2 (H2 relaxin), a hormone from the insulin-like family. Native relaxin consists of two chains linked by disulfide bridges. The B7-33 analogue is single-chain, which simplifies its structure and lets studies focus on one well described target: the RXFP1 receptor, a member of the G protein-coupled receptor family.

In vitro work describes selective activation of RXFP1 triggering cAMP-dependent pathways and nitric oxide related signaling. Native relaxin-2 and its recombinant form, serelaxin, were studied clinically in the context of acute heart failure. B7-33 is not a medicine and remains solely a laboratory research reagent.

In practice, B7-33 is often placed alongside other relaxin ligands in comparison systems. This makes it possible to separate the effects of RXFP1 activation alone from effects arising from other elements of the signaling network.

Side by side

Feature	ARA-290	B7-33
Parent protein	erythropoietin, helix B	relaxin-2 (H2 relaxin)
Structure	11 amino acids	single-chain analogue
Receptor described in studies	IRR (EPOR and CD131)	RXFP1
Main directions	tissue protection, nerves, inflammatory response	cAMP signaling, fibrosis, blood vessels
Format	lyophilized vial	lyophilized vial

The difference comes down to the research question. If a project concerns protective signaling in models of nerve or tissue damage, the natural starting point is ARA-290. If the focus is the RXFP1 receptor, fibroblast activity or remodeling of the extracellular matrix, B7-33 is worth a closer look.

Areas where both peptides appear

Both compounds are described in preclinical and in vitro research, so they often show up together in topic reviews. The areas most frequently mentioned include models of peripheral nerve damage and neuropathy in animal studies (ARA-290), tissue protection under ischemia and reperfusion (ARA-290), fibrosis models and fibroblast activity in cell systems (B7-33), and effects on blood vessels and nitric oxide dependent pathways (B7-33).

Each of these areas requires a separate project with its own controls and a clearly defined model. Peptides do not replace validation of the experimental system. They provide a well characterized reagent.

Reagent quality in practice

When results are compared, the repeatability of the material is what counts. Every batch of ARA-290 and B7-33 has a purity of at least 99% by HPLC, and the molecular mass is confirmed by mass spectrometry (MS). Both products are available as lyophilized vials, so portions can be measured out according to the protocol. We dispatch orders within 24 h: in Poland by InPost to a parcel locker, and across Europe by DPD. If you plan a series of experiments with both compounds, you can place them in one order and compare results from the same reagent family.

Planning a study with two peptides

Comparing two reagents requires as carefully designed a setup as the study itself. First, define which receptor or signaling pathway is the subject of the question. For ARA-290 that is usually the IRR complex, and for B7-33 the RXFP1 receptor. Only then choose the model: a cell line, a primary culture, or an animal system run under an approved protocol.

The second issue is controls. Every experiment should include a vehicle control with the same composition as the peptide solution. It is also worth deciding at the outset how often samples will be collected and which working concentration range the system uses. These ranges are set by the protocol rather than by general recommendations, so treat them as a starting point for your own pilot runs.

The third issue is reproducibility. If results will be compared across weeks or between teams, record the reagent batch number, the reconstitution date, the solvent used and the concentration of the working solution. Such records make it possible to trace any difference in the data back to its source.

Lab work with lyophilized peptides

Storage

Keep the lyophilizate at -20 °C, tightly sealed and protected from light and moisture. Before opening, let the vial reach room temperature to limit condensation inside. Once dissolved, keep the solution at 2-8 °C. Avoid repeated freezing and thawing, and divide the solution into smaller aliquots.

Reconstitution

Sterile bacteriostatic water is the solvent most often used to prepare the solution. The preservative in the water limits microbial growth when the vial is punctured many times. Acetic acid in dilution is sometimes used as an auxiliary solvent, depending on the protocol. The choice always follows the requirements of the specific experiment, so rely on your laboratory’s procedures.

After reconstitution, calculate the solution concentration by entering the vial mass and the solvent volume in the concentration calculator. This keeps the aliquots for later experiments reproducible and makes the research record unambiguous.